ÌÇÐÄvlog´«Ã½

Market Share of Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Industry

The pharmaceutical CDMO market is highly fragmented. Major vendors account for the majority of the market share. The presence of many players impacts the pricing of services, making it a direct competing factor, especially for small-scale vendors. The vendors are expected to focus on delivering one-stop-shop services, providing them with a competitive advantage. These practices would be possible for the CMOs with access to significant capital. This factor increases the competition and acts as an entry barrier for new players. The market faces competition from other CROs and from a wide range of vendors, varying from cloud-based data management tool providers to individual solution providers. In countries where there is a high presence of pharma and biotech research activity, the competitive rivalry is especially high. Some of the major players in the market are Catalent Inc., Recipharm AB, Jubilant Pharmova Ltd, Patheon Inc. (Thermo Fisher Scientific Inc.), and Boehringer Ingelheim Group.

• In February 2024, Catalent Inc. and Novo Holdings entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at USD 16.5 billion.
• In February 2024, Recipharm, a contract development and manufacturing organization, entered into an exclusive licensing and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination pharmaceutical products.
• In January 2024, Parexel and the Japanese Foundation for Cancer Research announced a strategic alliance to accelerate access to oncology clinical trials in Japan.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Leaders

1. Catalent Inc.

2. Recipharm AB

3. Jubilant Pharmova Ltd

4. Patheon Inc. (Thermo Fisher Scientific Inc.)

5. Boehringer Ingelheim Group

*Disclaimer: Major Players sorted in no particular order